March 29, 2018 / 7:11 AM / in 4 months

BRIEF-‍Indivior Says Enters Into License Agreement For C4x Discovery's OX1 Antagonist Program​

March 29 (Reuters) - Indivior Plc:

* ‍INDIVIOR ENTERS INTO AN EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR C4X DISCOVERY’S OREXIN-1 (OX1) ANTAGONIST PROGRAM​

* ‍INDIVIOR UK LIMITED AND C4X DISCOVERY HOLDINGS PLC ENTERED INTO A LICENSE AGREEMENT​

* INDIVIOR - ‍UNDER AGREEMENT, INDIVIOR UK OBTAINED EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE C4X’S ORAL OREXIN-1 RECEPTOR ANTAGONIST PROGRAM​

* INDIVIOR - ‍INDIVIOR UK WILL MAKE AN UPFRONT PAYMENT TO C4X OF $10 MILLION WITH POTENTIAL MILESTONE PAYMENTS TO C4X THAT COULD TOTAL $284 MILLION OVER TIME​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below